store at low temperature
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Salinomycin (Procoxacin), a polyether potassium ionophore antibiotic, specifically inhibits the growth of gram-positive bacteria. It acts as a potent inhibitor of Wnt/β-catenin signaling, blocking Wnt-induced LRP6 phosphorylation. Additionally, Salinomycin (Procoxacin) demonstrates selective activity against human cancer stem cells.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 32.00 | |
2 mg | In stock | $ 45.00 | |
5 mg | In stock | $ 74.00 | |
10 mg | In stock | $ 118.00 | |
25 mg | In stock | $ 219.00 | |
50 mg | In stock | $ 389.00 | |
100 mg | In stock | $ 558.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 128.00 |
Description | Salinomycin (Procoxacin), a polyether potassium ionophore antibiotic, specifically inhibits the growth of gram-positive bacteria. It acts as a potent inhibitor of Wnt/β-catenin signaling, blocking Wnt-induced LRP6 phosphorylation. Additionally, Salinomycin (Procoxacin) demonstrates selective activity against human cancer stem cells. |
In vitro | Salinomycin, a potent Wnt signaling cascade inhibitor and antibiotic potassium ionophore, demonstrates significant anticancer properties. It induces apoptosis in malignant lymphocytes within 48 hours, showing a mean IC50 value of 230 nM. Notably, Salinomycin has been identified as a selective inhibitor of breast cancer stem cells (CSCs)[1], effectively inhibiting both normal and Cisp-resistant SW620 cancer cells with IC50 values of 1.54±0.23 μM and 0.32±0.05 μM, respectively. It uniquely targets and kills CSCs and therapy-resistant cancer cells. Continuous treatment with Salinomycin over 48 hours increases the apoptotic cell count significantly in Cisp-resistant SW620 cells compared to non-resistant SW620 cells, as observed under a microscope and confirmed through flow cytometric analysis of cell apoptosis. The apoptotic rate is markedly higher in Cisp-resistant SW620 cells (37.82±3.63%) than in standard SW620 cells (16.78±2.56%) (p<0.05)[2]. |
In vivo | Upon administering doses of 4 mg/kg and 8 mg/kg Salinomycin (Sal), alongside 10 uL/g saline water to mice for a duration of 6 weeks, followed by their sacrifice, a significant reduction in liver tumor size is observed in the Sal-treated groups compared to the controls. Tumor diameters decrease notably from 12.17 mm to 3.67 mm (p<0.05), and volumes, calculated as V=length×width^2×0.5, diminish from 819 mm^3 to 25.25 mm^3 (p<0.05). Subsequent analyses, involving HE staining, immunohistochemistry, and TUNEL assays, are conducted to evaluate Salinomycin's anti-tumor efficacy. Results show altered liver cancer tissue structure, reduced PCNA expression, and higher apoptosis rates in Sal-treated mice, indicating significant anti-tumor activity. Furthermore, an increase in the Bax/Bcl-2 ratio and a decrease in β-catenin protein expression corroborate Salinomycin's effectiveness. Salinomycin, a monocarboxylic acid polyether antibiotic derived from Streptomyces albus fermentation, exhibits a unique cyclic structure enabling it to bind with pathogenic microorganisms and extracellular cations of coccidia, particularly K+, Na+, Rb+, effectively altering intra- and extracellular ion concentrations[4][5]. |
Synonyms | Procoxacin |
Molecular Weight | 751 |
Formula | C42H70O11 |
CAS No. | 53003-10-4 |
store at low temperature
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 35 mg/mL (46.6 mM), Sonication is recommended.
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Salinomycin 53003-10-4 Cytoskeletal Signaling Microbiology/Virology Stem Cells Wnt/beta-catenin Antibacterial Procoxacin inhibitor inhibit